Literature DB >> 17208468

Human umbilical cord blood serum can replace fetal bovine serum in the culture of mesenchymal stem cells.

P Shetty1, K Bharucha, V Tanavde.   

Abstract

The potential of mesenchymal stem cells (MSC) to differentiate into different cell types has opened up the possibility of using these cells clinically to treat a variety of disorders. In this study we describe the use of human umbilical cord blood serum (CBS) as a replacement for fetal bovine serum (FBS) for culturing MSC from different sources. MSC from human and swine bone marrow and human umbilical cord blood were cultured in the presence of DMEM/F12 containing either FBS or CBS. Human MSC cultured in presence of FBS or CBS showed typical fibroblast-like morphology, which is characteristic of MSC. 99% of the cells cultured in FBS had a CD73+/CD105+/CD45- phenotype compared to 96% of cells cultured in CBS. Cells cultured in CBS had a significantly higher cell count as compared to cells cultured in FBS. Swine Bone Marrow MSC cultured in the presence of FBS and CBS were morphologically and phenotypically similar. Human umbilical cord blood serum supports the growth of MSC. While no significant differences were observed in the MSC numbers in swine cells cultured in the presence of FBS or CBS, human cells showed a greater proliferation potential in the presence of CBS as compared to FBS. Therefore, CBS can be used as an effective substitute to FBS for developing clinically useful protocols for culturing MSC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17208468     DOI: 10.1016/j.cellbi.2006.11.010

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  31 in total

1.  A rapid and efficient method for primary culture of human adipose-derived stem cells.

Authors:  Guofang Zeng; Kuan Lai; Jin Li; Yaqin Zou; Haili Huang; Jie Liang; Xudong Tang; Jing Wei; Peihua Zhang
Journal:  Organogenesis       Date:  2013-11-22       Impact factor: 2.500

2.  Cord blood serum harvesting by hydroxyethyl starch: a fetal bovine serum alternative in expansion of umbilical cord-derived mesenchymal stem cells.

Authors:  Maryam Samareh Salavati Pour; Reza Vahidi; Mahla Lashkari; Ali Derakhshani; Zahra Ameri; Alireza Farsinejad
Journal:  Cytotechnology       Date:  2020-06-29       Impact factor: 2.058

Review 3.  Regenerative Therapy Using Umbilical Cord Serum.

Authors:  Nagarajan Maharajan; Gwang-Won Cho; Ji Hyun Choi; Chul Ho Jang
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 4.  Explant culture: An advantageous method for isolation of mesenchymal stem cells from human tissues.

Authors:  Fatemeh Hendijani
Journal:  Cell Prolif       Date:  2017-02-01       Impact factor: 6.831

5.  Derivation, expansion and characterization of clinical grade mesenchymal stem cells from umbilical cord matrix using cord blood serum.

Authors:  Khushnuma Cooper; Anish SenMajumdar; Chandra Viswanathan
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

Review 6.  Influences of Xeno-Free Media on Mesenchymal Stem Cell Expansion for Clinical Application.

Authors:  Hue Thi Hong Bui; Liem Thanh Nguyen; Uyen Thi Trang Than
Journal:  Tissue Eng Regen Med       Date:  2020-11-04       Impact factor: 4.169

7.  Culture and in vitro hepatogenic differentiation of placenta-derived stem cells, using placental extract as an alternative to serum.

Authors:  K S Shin; H J Lee; J Jung; D H Cha; G J Kim
Journal:  Cell Prolif       Date:  2010-10       Impact factor: 6.831

8.  Human umbilical cord-derived MSC culture: the replacement of animal sera with human cord blood plasma.

Authors:  Yan Ding; Hua Yang; Jing Bo Feng; Ying Qiu; Dong Sheng Li; Yi Zeng
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-09-17       Impact factor: 2.416

9.  Upregulation of Adipogenesis and Chondrogenesis in MSC Serum-Free Culture.

Authors:  Saey Tuan Barnabas Ho; Vivek Madhukar Tanavde; James Hoi Hui; Eng Hin Lee
Journal:  Cell Med       Date:  2011-06-01

10.  Comparative analyses of industrial-scale human platelet lysate preparations.

Authors:  Jan Pierce; Eric Benedetti; Amber Preslar; Pam Jacobson; Ping Jin; David F Stroncek; Jo-Anna Reems
Journal:  Transfusion       Date:  2017-10-08       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.